Isomorphic Labs raises $5 billion in Series C funding for AI drug discovery


    The Google DeepMind spin-off plans to use the funds to advance its AI drug discovery programmes and move its first drug candidates towards clinical trials.

    The Google DeepMind spin-off plans to use the funds to advance its AI drug discovery programmes and move its first drug candidates towards clinical trials.

    Isomorphic Labs said on Tuesday it
    has raised $5 billion in ​a Series C funding round co-led ‌by
    Greenoaks and Sequoia Capital, as the ​Alphabet-backed
    AI drug discovery company ⁠works to move its first drug
    candidates into clinical trials.

    The company, which was spun ‌out of Google DeepMind in 2021,
    declined to share its ‌valuation. The funding comes about ‌six
    months ⁠after it raised $2.1 billion in ⁠a Series B round led by
    Thrive Capital.

    Here are more details:

    * Andreessen Horowitz and other ​new investors joined ‌the
    round, while Alphabet made a significant investment and other
    existing backers, including Thrive, MGX and GV, also
    participated

    * “This ‌round enables us to accelerate ​our progress:
    building foundational biology models, deepening our systemic
    disease understanding, and ⁠driving our first therapeutic
    programs towards clinical trials to deliver tangible impact for
    patients,” ‌Isomorphic founder and CEO Demis Hassabis said

    * The company is developing its IsoDDE drug design engine,
    which uses AI to design new drugs, predict their properties and
    refine them ‌before scientists decide on the candidates to ​make
    and test

    * Isomorphic said it has seen positive pre-clinical ⁠results
    in internal oncology and immunology programs and ⁠with partners,
    “setting the stage for clinical entry”

    * The company lists ‌Novartis, Eli Lilly and
    Johnson & Johnson as its partners, according to ​its
    website

    Published on November 17, 2026



    Source link